Liminatus Pharma Statistics
Liminatus Pharma (LIMN) Stock Statistics & Valuation Metrics
Total Valuation
Liminatus Pharma has a market cap or net worth of $3.41M. The enterprise value is $2.81T.
- Market Cap
- $3.41M
- Enterprise Value
- $2.81T
Share Statistics
Liminatus Pharma has 1,343,208 shares outstanding. The number of shares has decreased by -2.65% in one year.
- Shares Outstanding
- 1,343,208
- Owned by Insiders
- 2.67%
- Owned by Institutions
- 0.28%
Financial Efficiency
Liminatus Pharma’s return on equity (ROE) is 1.04 and return on invested capital (ROIC) is 35.57%.
- Return on Equity (ROE)
- 1.04
- Return on Assets (ROA)
- -19.90
- Return on Invested Capital (ROIC)
- 35.57%
- Return on Capital Employed (ROCE)
- 0.30
- Revenue Per Employee
- 0
- Profits Per Employee
- -10.21M
- Employee Count
- 1
- Asset Turnover
- 0.00
- Inventory Turnover
- 0.00
Valuation Ratios
The current PE Ratio of Liminatus Pharma is -0.11. Liminatus Pharma’s PEG ratio is -0.00.
- PE Ratio
- -0.11
- PS Ratio
- 0.00
- PB Ratio
- 4.28
- Price to FCF
- -0.91
- Price to Operating Cash Flow
- -0.32
- PEG Ratio
- -0.00
Income Statement
In the last 12 months, Liminatus Pharma had revenue of 0 and earned -10.21M in profits. Earnings per share was -21.50.
- Revenue
- 0
- Gross Profit
- 0
- Operating Income
- -2.97M
- Pretax Income
- -10.21M
- Net Income
- -10.21M
- EBITDA
- -9.99M
- Earnings Per Share (EPS)
- -21.50
Cash Flow
In the last 12 months, operating cash flow was -3.97M and capital expenditures -13,111, giving a free cash flow of -3.99M billion.
- Operating Cash Flow
- -3.97M
- Free Cash Flow
- -3.99M
- Free Cash Flow per Share
- -8.39
Dividends & Yields
Liminatus Pharma pays an annual dividend of ―, resulting in a dividend yield of ―
- Dividend Per Share
- ―
- Dividend Yield
- ―
- Payout Ratio
- N/A
- Free Cash Flow Yield
- -111.14%
- Earnings Yield
- -987.30%
Stock Price Statistics
- Beta
- 2.41
- 52-Week Price Change
- -96.03%
- 50-Day Moving Average
- 3.45
- 200-Day Moving Average
- 9.52
- Relative Strength Index (RSI)
- 33.55
- Average Volume (3m)
- 216.35K
Financial Position
Liminatus Pharma as a current ratio of 0.05, with Debt / Equity ratio of -14.70%
- Current Ratio
- 0.05
- Quick Ratio
- 0.05
- Debt to Market Cap
- 0.10
- Net Debt to EBITDA
- -0.11
- Interest Coverage Ratio
- -13.75
Taxes
In the past 12 months, Liminatus Pharma has paid 0 in taxes.
- Income Tax
- 0
- Effective Tax Rate
- 0.00
Enterprise Valuation
Liminatus Pharma EV to EBITDA ratio is -0.16, with an EV/FCF ratio of -0.50.
- EV to Sales
- 0.00
- EV to EBITDA
- -0.16
- EV to Free Cash Flow
- -0.50
- EV to Operating Cash Flow
- -0.51
Balance Sheet
Liminatus Pharma has $3.02M in cash and marketable securities with $1.44M in debt, giving a net cash position of $1.57M billion.
- Cash & Marketable Securities
- $3.02M
- Total Debt
- $1.44M
- Net Cash
- $1.57M
- Net Cash Per Share
- $1.17
- Tangible Book Value Per Share
- $0.63
Margins
Gross margin is 0.00%, with operating margin of 0.00%, and net profit margin of 0.00%.
- Gross Margin
- 0.00%
- Operating Margin
- 0.00%
- Pretax Margin
- 0.00%
- Net Profit Margin
- 0.00%
- EBITDA Margin
- 0.00%
- EBIT Margin
- 0.00%
Analyst Forecast
The average price target for Liminatus Pharma is ―, which is 11.43% higher than the current price. The consensus rating is ―
- Price Target
- ―
- Price Target Upside
- ―
- Analyst Consensus
- ―
- Analyst Count
- ―
- Revenue Growth Forecast
- ―
- EPS Growth Forecast
- -107.04%
